Artificial intelligence news.
Straight from the original announcements.

Withings Body Pro 3 brings segmental body composition tracking home

November 12, 2026, 13:15By the AI News Bites Editorial TeamSource: PR Newswire
Withings Body Pro 3 brings segmental body composition tracking home
Image: PR Newswire

Withings Health Solutions has unveiled Body Pro 3, a cellular health station designed to give weight management and GLP-1 programs more information than a conventional weigh-in. The device adds segmental fat and muscle estimates, progress projections and a hypertension notification feature that is pending FDA 510(k) clearance.

Key points
  • Body Pro 3 estimates segmental fat and muscle for the arms, legs and torso.
  • Its model forecasts weight, fat mass and muscle mass across GLP-1 journeys.
  • A hypertension notification feature is pending FDA 510(k) clearance.
  • The device is planned for enterprise and clinical programs in early 2027.

From weight readings to body composition

Body Pro 3 uses a new retractable handle to provide estimated fat and muscle readings for each arm, leg and the torso. It also produces a visceral fat index, giving care teams information that weight and BMI alone do not provide.

Withings says a 2025 validation study comparing its readings with DEXA, described as the clinical gold standard, found correlations of 0.99 for fat mass and 0.98 for lean and muscle mass. The company presents the feature as DEXA-level segmental body composition tracking for use at home.

The device is intended to turn routine weigh-ins into clinical information for care teams and members. Withings Health Solutions Vice President Antoine Pivron said Body Pro 3 is designed to address muscle preservation and member engagement in GLP-1 programs, while allowing care teams to intervene when progress begins to drift.

Forecasts and a pending hypertension feature

Body Pro 3's predictive model is built on tens of thousands of GLP-1 journeys, according to Withings. With each weigh-in, it forecasts weight, fat mass and muscle mass, then uses those projections to create a personalized Goal Probability Score and Off-Track Alerts.

Withings describes the projections as estimates, not guarantees. The company says the alerts are intended to show members and care teams where progress may be heading, rather than simply recording a current measurement.

A hypertension notification feature analyzes weigh-in data for patterns suggestive of hypertension and notifies the care team to seek further clinical evaluation. It does not measure blood pressure, replace a blood pressure measurement or function as a standalone diagnostic tool. The feature is pending FDA 510(k) clearance and is not available for sale in the United States at this time. It is intended for adults 22 and older who have not previously been diagnosed with hypertension, and is not for use in pregnancy.

Focus on GLP-1 care and clinical programs

Withings Health Solutions cited a 2025 JAMA Network Open study of 125,474 adults with overweight or obesity, which found that about 54% stopped GLP-1 therapy within a year. The figure rose to about 65% among people without type 2 diabetes, according to the company.

Body Pro 3 is aimed at enterprise healthcare partners, remote patient monitoring providers and clinical weight management programs. Withings Health Solutions says the additional data may help care teams monitor changes in muscle and fat between visits and support decisions involving protein intake, resistance training or medication titration.

The company says Body Pro 3 will be available in early 2027. It will be showcased alongside Withings' connected health devices at HLTH 2026 in Las Vegas from November 15 to 18.

Withings Health SolutionsBody Pro 3GLP-1FDAhealthcareenterprise AI

Related news

Bracco Wins FDA Clearance for AI Brain Aneurysm Software
Products and toolsNovember 13, 2026, 08:00

Bracco Wins FDA Clearance for AI Brain Aneurysm Software

Bracco and Avicenna.AI have received U.S. Food and Drug Administration 510(k) clearance for UPTUNITY™ | Aneurysm, an AI-enabled software tool for detecting and assessing…

Research
ResearchNovember 3, 2026, 11:48

Differentia Bio's AI models matched later clinical outcomes

Differentia Bio says its disease-modeling platform identified therapeutic mechanisms between 2023 and 2024 that were later supported by independent clinical results. One…

Vanda's NEREUS Cuts Semaglutide-Induced Vomiting in Phase III Trial
ResearchOctober 27, 2026, 11:50

Vanda's NEREUS Cuts Semaglutide-Induced Vomiting in Phase III Trial

Vanda Pharmaceuticals says its oral drug NEREUS (tradipitant) significantly reduced vomiting caused by semaglutide in the Phase III Study 3601. The company plans to…